HER2-negative breast cancer

Researchers are studying giredestrant, an experimental daily pill, in people with estrogen receptor-positive, HER2-negative early breast cancer. The trial enrolls about 1,500 participants, including some who switch to giredestrant after other treatments. It tracks how many people…

This trial is testing an investigational drug called SKB103 in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study has two parts: first, to find a safe dose, and second, to see how well that dose shrinks tumors. Participants r…

This phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…

This phase II trial tests whether combining multi-mode thermal therapy (heat treatment) with immunotherapy drugs can help people with HER2-negative breast cancer that has spread to the liver. The study will enroll 30 participants who have already tried at least one prior treatmen…

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…

This study tests whether training doctors in shared decision-making and giving patients educational materials improves treatment conversations for HER2-negative metastatic breast cancer. 120 patients starting first-line therapy will be randomly assigned to receive the program or …